Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating the current MRD testing landscape including Signatera from Natera Oncology, Reveal from Guardant Health, and ClonoSEQ from Adaptive Biotech.

Ticker(s): NTRA, GH, ADPT

Who's the expert?

Institution: Cancer Specialists of North Florida

Hematologist and oncologist with Cancer Specialists of North Florida; former Associate Professor of Oncology and Medical Director of the Cancer Center at Johns Hopkins.
Treats over 100 patients with blood cancers and solid tumors and has ordered Clonoseq, Signatera, and Reveal tests.
Nationally recognized for his expertise in blood-related cancers and conditions, and has numerous articles, presentations at conferences and book chapters to his name.

Interview Goal

This call will focus on the current Measurable residual disease (MRD) tests available for solid tumors and blood cancers. There will be an emphasis on three current tests, Signatera from Natera Oncology, Reveal from Guardant Health, and ClonoSEQ from Adaptive Biotech. The call will also include perspectives from an oncologist who has ordered all three of these tests.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.